

DAFTAR PUSTAKA

- Alphs, L. D., Summerfelt, A., Lann, H. & Muller, R. J., 1989. The Negative Symptom Assessment: A New Instrument to Assess Negative Symptoms in Schizophrenia. *Psychopharmacology Bulletin*, 25(2), pp. 159-163.
- Andreasen, N. C., 1989. The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations. *British Journal of Psychiatry*, 155(7), pp. 49-52.
- Aosaki, T. et al., 2010. Acetylcholine–dopamine balance hypothesis in the striatum: An update. *Japan Geriatrics Society*, 10(1), pp. 148-157.
- Axelrod, B. N., Goldman, R. S. & Alphs, L. D., 1993. Validation of the 16-item Negative Symptom Assessment. *J Psychiatr Res*, 27(3), pp. 253-258.
- Cerveri, G., Gesi, C. & Mencacci, C., 2019. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. *Neuropsychiatr Dis Treat*, Volume 15, pp. 1525-1535.
- Chen, J., Cao, H., Meyer-Lindenberg, A. & Schwarz, E., 2018. Male increase in brain gene expression variability is linked to genetic risk for schizophrenia. *Translational Psychiatry*, Volume 8, p. 140.
- Chou, I.-J. et al., 2017. Familial Aggregation and Heritability of Schizophrenia and Co-aggregation of Psychiatric Illnesses in Affected Families. *Schizophrenia Bulletin*, 43(5), p. 1070–1078.
- Correll, C. U. & Schooler, N. R., 2020. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. *Neuropsychiatr Dis Treat*, Issue 16, pp. 519-534.
- Dahlan, M. S., 2009. *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*. Jakarta: Salemba Medika.
- Darsana, I. W. & Suariyani, N. L. P., 2020. TREND KARAKTERISTIK DEMOGRAFI PASIEN SKIZOFRENIA DI RUMAH SAKIT JIWA PROVINSI BALI (2013-2018). *Arc. Com. Health*, 7(1), pp. 41-51.

- De Berardis, D. et al., 2018. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of Clozapine. *Ther Adv Drug Saf*, 5(9), pp. 237-256.
- Dennis, J. A., Gittner, L. S., Payne, J. D. & Nugent, K., 2020. Characteristics of U.S. adults taking prescription antipsychotic medications, National Health and Nutrition Examination Survey 2013–2018. *BMC Psychiatry*, Volume 20, p. 483.
- Dwanti, O., Rizkifani, S. & Susanti, R., 2020. *Jurnal Untan*. [Online] Available at: <https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjYsNef8vT5AhWl7TgGHbDtDWoQFnoECBgQAQ&url=https%3A%2F%2Fjurnal.untan.ac.id%2Findex.php%2Fjmfarmasi%2Farticle%2Fdownload%2F55716%2F75676593551&usg=AOvVaw0jaS3-TDDqcOs4cifSIq4> [Accessed 2 September 2022].
- Flanagan, R. J. et al., 2020. Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals. *British Medical Bulletin*, Volume 135, p. 73–89.
- Fujimaki, K., Takahashi, T. & Morinobu, S., 2012. Association of Typical versus Atypical Antipsychotics with Symptoms and Quality of Life in Schizophrenia. *Plos One*, 7(5), pp. 1-10.
- Fusar-Poli, P. et al., 2015. Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. *Schizophrenia Bull*, 4(41), pp. 892-899.
- Galling, B. et al., 2017. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. *World Psychiatry*, 1(16), pp. 77-89.
- Garcia-Alvarez, L. et al., 2018. Spanish validation of the Negative Symptom Assessment-16 (NSA-16) in patients with schizophrenia. *Revista de Psiquiatría y Salud Mental*, 11(3), pp. 169-175.

- Glenthøj, L. B. et al., 2020. Experiential negative symptoms are more predictive of real-life functional outcome than expressive negative symptoms in clinical high- risk states. *Schizophrenia Research*, pp. 1-6.
- Haro, J. et al., 2003. The Clinical Global Impression– Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. *Acta Psychiatr Scand* , 107(416), pp. 16-23.
- He, H. et al., 2020. Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017. *Epidemiology and Psychiatric Sciences*, 29(e91), pp. 1-11.
- Hendriati, D., 2019. *Perbedaan Skor PANSS Skala Negatif Antara Laki-laki dengan Skizofrenia yang Mendapat Pengobatan Risperidon dengan Penambahan N-Acetylcystein dan yang Hanya Mendapat Pengobatan Risperidon di Rumah Sakit Jiwa Prof. DR. Muhammad Ildrem Medan*. Sumatera Utara, Indonesia: Universitas Sumaera Utara.
- Holm, M. et al., 2020. Employment among people with schizophrenia or bipolar disorder: A population-based study using nationwide registers. *Acta Psychiatrica Scandinavica*, Volume 143, pp. 61-71.
- Honer, W. G. et al., 2006. Clozapine alone versus Clozapine and Risperidone with refractory schizophrenia. *N Engl J Med* , 5(354), pp. 472-482.
- Hori, H. et al., 2022. Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics. *Frontiers in Psychiatry* , Volume 13, pp. 1-11.
- Idaiani, S. et al., 2019. Prevalensi Psikosis di Indonesia berdasarkan Riset Kesehatan Dasar 2018. *Jurnal Penelitian dan Pengembangan Pelayanan Kesehatan*, 3(1).
- Jablensky, A., 2010. The diagnostic concept of schizophrenia: its history, evolution, and future prospects. *State of the art*, Volume 12, pp. 271-287.
- Josiassen, R. C. et al., 2005. Clozapine augmented with Risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. *Am J Psychiatry*, 1(162), pp. 130-136.

- Kay, S. R., Fiszbein, A. & Opler, L. A., 1987. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. *Schizophrenia Bulletin*, 13(2), pp. 261-276.
- Kemmler, G., Hummer, M., Widschwendter, C. & Fleischhacker, W., 2005. Dropout Rates in Placebo-Controlled and Active-Control Clinical Trials of Antipsychotic Drugs. *American Medical Association*, 62(2), pp. 1305-1312.
- Kirkpatrick, B. et al., 2011. The Brief Negative Symptom Scale: Psychometric Properties. *Schizophrenia Bulletin*, 37(2), pp. 300-305.
- Kirkpatrick, B., Fenton, W. S., Carpenter, Jr, W. T. & Marder, S. R., 2006. The NIMH-MATRICES Consensus Statement on Negative Symptoms. *Schizophrenia Bulletin*, 32(2), pp. 214-219.
- Krause, M. et al., 2018. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. *Eur Arch Psychiatry Clin Neurosci*, 7(268), pp. 625-639.
- Kring, A. M. et al., 2013. The Clinical Assessment Interview for Negative Symptoms (CAINS): Final Development and Validation. *Am J Psychiatry*, 170(2), pp. 165-172.
- Leon, J. d. et al., 2019. Do Asian Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Overview. *Indian Psychiatric Society*, Volume 42, pp. 4-10.
- LKPP, L.K.P.B.P., 2020. *E-Catalogue*. [Online] Available at: <https://e-katalog.lkpp.go.id/id/search-produk?authenticityToken=0b74f664265daf076040485d5c44c0eab11ad43f&q=rispe&prid=&pid=>=<=&mid=&kbid=&order=&cat=> [Accessed 5 September 2022].
- Lorentzen, R. et al., 2022. The efficacy of transcranial magnetic stimulation (TMS) for negative symptoms in schizophrenia: a systematic review and meta-analysis. *Schizophrenia*, 8(35), pp. 1-12.
- McHugh, M. L., 2012. Interrater reliability: the kappa statistic. *Biochemia Medica*, 3(22), pp. 276-282.

- Mcleod, H. J., Gumley, A. & Schwannaeur, M., 2014. The Impact of Metacognition on the Development and Maintenance of Negative Symptoms. In: P. H. Lysaker, G. Dimaggio & M. Brüne , eds. *Social Cognition and Metacognition in Schizophrenia: Psychopathology and Treatment Approaches*. Glasgow: Academic Press, pp. 115-136.
- Misdrahi, D. et al., 2019. Prevalence of and Risk Factors for Extrapyrarnidal Side Effects of Antipsychotics. *SME*, Volume 1, p. 80.
- Muralidharan, A., Harvey, P. D. & Bowie, C. R., 2018. Associations of Age and Gender with Negative Symptom Factors and Functioning Among Middle-Aged and Older Adults with Schizophrenia. *Am J Geriatr Psychiatry*, 12(26), pp. 1215-1219.
- Novick, D., Montgomery, W., Moneta, V. & Haro, J., 2015. Impact of Negative Symptoms on Quality of Life in Patients with Schizophrenia. *MENTAL HEALTH – CLINICAL OUTCOMES STUDIES*, 18(7), pp. 805-881.
- Orrico-Sánchez, A., López-Lacort, M. & Muñoz-Qui, C., 2020. Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain. *BMC Psychiatry*, Volume 20, p. 149.
- Pedersen, C. B. et al., 2022. Urban-Rural Differences in Schizophrenia Risk: Multilevel Survival Analyses of Individual- and Neighborhood-Level Indicators, Urbanicity and Population Density in a Danish National Cohort Study. *Schizophrenia Bulletin Open*, 3(1).
- Purwandityo, A. G. et al., 2018. Pengaruh Antipsikotik terhadap Penurunan Skor The Positive and Negative Syndrome Scale-Excited Component. *Jurnal Farmasi Klinik Indonesia*, 7(1).
- Riehlea, M., Böhla, M. C., Pillnya, M. & Lincoln, T. M., 2020. Efficacy of Psychological Treatments for Patients With Schizophrenia and Relevant Negative Symptoms: A Meta-Analysis. *Clinical Psychology in Europe*, 2(3), pp. 1-23.
- Riskesdas, 2018. *Infodatin*, Indonesia: Kementerian Kesehatan RI.

- Roiter, B., Pigato, G. & Antonini, A., 2020. Prevalence of Extrapyrimaldal Symptoms in In-Patients With Severe Mental Illnesses: Focus on Parkinsonism. *Frontiers in Neurology*, Volume 11, pp. 1-7.
- RSJ Prof Soerojo, 2022. *Jumlah Pasien Skizofrenia Rawat Jalan dan Rawat Inap Tahun 2021*. Jawa tengah, Indonesia: s.n.
- Sadock, B. J., Sadock, V. A. & Ruiz, P., 2017. Schizophrenia and Other Psychotic Disorders. In: *Kaplan & Sadock's Comprehensive Textbook of Psychiatry*. Philadelphia: Wolters Kluwer, pp. 3613-3664.
- Sanz-Fuentenebro, J. et al., 2013. Randomized trial of Clozapine vs. Risperidone in treatment-naïve first-episode schizophrenia: Results after one year. *Schizophrenia Research*, Volume 30, pp. 1-6.
- Siskind, D., McCartney, L., Goldschl, R. & Kisely, S., 2016. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. *Br J Psychiatry*, 5(209), pp. 385-392.
- Stahl, S. M., 2013. Psychosis and Schizophrenia. In: *Stahl's Essential Psychopharmacology*. Newyork: Cambridge University Press, p. 79.
- Tattan, T. M. & Creed, F. H., 2001. Negative Symptoms of Schizophrenia and Compliance with Medication. *Schizophrenia Bulletin*, 27(1), pp. 149-155.
- Thornton, . A. E., Pomarol-Clotet, E. & Chen, E., 2006. Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia. *New England Journal of Medicine*, 5(354), pp. 472-82.
- Utmukarti, N., 2018. *Kajian Penggunaan Antipsikotik pada Pengobatan Pertama Pasien Skizofrenia Anak-Remaja di Rumah Sakit Jiwa Prof. Dr. Soerojo Magelang*. Yogyakarta, Indonesia: Program Studi Farmasi Fakultas Matematika dan Ilmu Pengetahuan Alam Universitas Islam Indonesia.
- Weiner, E. et al., 2010. Adjunctive Risperidone for partially responsive people with schizophrenia treated with Clozapine. *Neuropsychopharmacology*, 35(11), pp. 2274-2283.
- WHO, 2019. *World Health Organization*. [Online] Available at: <https://www.who.int/news-room/fact->

[sheets/detail/schizophrenia](#)

[Accessed 2 February 2022].

Yildiz, M., Incedere, A., GÜrcan, M. B. & Osman, E., 2022. Brief Clinical Assessment Scale for Schizophrenia (BCASS): Development, Validity, and Reliability Study. *Arch Neuropsychiatry*, Volume 59, pp. 14-20.